Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Maschmeyer

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|May 1, 1995
Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AMLC Sperling, T Büchner, U Creutzig, et al.
Haematology and Blood Transfusion|January 1, 1987
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative GroupT Büchner, W Hiddemann, D Urbanitz, et al.
Leukemia|November 1, 1992
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AMLT Büchner, W Hiddemann, U W Schaefer, et al.
Leukemia & Lymphoma|January 1, 1993
The role of GM-CSF in the treatment of acute myeloid leukemiaT Büchner, W Hiddemann, B Wörmann, et al.
Onkologie|February 1, 1987
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies]T Büchner, D Urbanitz, W Hiddemann, et al.
Onkologie|April 1, 1986
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies]T Büchner, D Urbanitz, W Hiddemann, et al.
Annals of Hematology|March 1, 1993
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial resultsA Ganser, G Heil, K Kolbe, et al.
Leukemia & Lymphoma|January 1, 1993
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparisonW Hiddemann, C Aul, G Maschmeyer, et al.
Cancer|September 1, 1990
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study GroupW Hiddemann, N Schmitz, M Pfreundschuh, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 29, 2012
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter studyG Maschmeyer, W J Heinz, B Hertenstein, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|May 1, 1995
Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AMLC Sperling, T Büchner, U Creutzig, et al.
Haematology and Blood Transfusion|January 1, 1987
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative GroupT Büchner, W Hiddemann, D Urbanitz, et al.
Leukemia|November 1, 1992
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AMLT Büchner, W Hiddemann, U W Schaefer, et al.
Leukemia & Lymphoma|January 1, 1993
The role of GM-CSF in the treatment of acute myeloid leukemiaT Büchner, W Hiddemann, B Wörmann, et al.
Onkologie|February 1, 1987
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies]T Büchner, D Urbanitz, W Hiddemann, et al.
Onkologie|April 1, 1986
[Acute myeloid leukemia (AML) in adults. Further development of therapy based on clinical phase II and phase III studies]T Büchner, D Urbanitz, W Hiddemann, et al.
Annals of Hematology|March 1, 1993
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial resultsA Ganser, G Heil, K Kolbe, et al.
Leukemia & Lymphoma|January 1, 1993
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparisonW Hiddemann, C Aul, G Maschmeyer, et al.
Cancer|September 1, 1990
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study GroupW Hiddemann, N Schmitz, M Pfreundschuh, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 29, 2012
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter studyG Maschmeyer, W J Heinz, B Hertenstein, et al.
Pageof 9